Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Medical Genetics

Finding Stability with HMBS-Related Hepatic Porphyria

At a Glance

HMBS-related hepatic porphyria, or Acute Intermittent Porphyria (AIP), is a genetic metabolic disorder. Most people with the gene never develop symptoms. For those who do, severe abdominal pain attacks can be prevented by avoiding triggers like fasting, alcohol, and certain medications.

Receiving a diagnosis of HMBS-related hepatic porphyria, more commonly known as Acute Intermittent Porphyria (AIP), often comes after a long and exhausting search for answers. Because the symptoms—like severe abdominal pain—can mimic many other conditions, many patients spend years visiting different specialists before finding the right diagnosis [1][2].

It is important to know that while this is a genetic condition, it does not define your health. Most people who carry the genetic change will never experience a single symptom [3][4]. Understanding how your body works and what it needs is the first step toward living a full, healthy life.

Understanding Your Diagnosis

AIP is a metabolic disorder caused by a change in the HMBS gene [5]. This gene provides instructions for making an enzyme called porphobilinogen deaminase (PBGD) [5]. This enzyme is part of the process that creates heme, a vital component of blood and the liver [6].

When this enzyme isn’t working at full capacity, the liver can sometimes struggle to keep up. If the liver is pushed too hard by certain triggers, it can produce an excess of two substances: delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) [5][2]. When these build up to high levels, they can become toxic to your nervous system, leading to what is called an “acute attack” [2].

The Mystery of Low Penetrance

You may have heard that only about 1% to 2% of people with the HMBS mutation ever develop symptoms [3][6]. This is called low penetrance, which means the “blueprint” (the gene) is there, but the “house” (the disease) is rarely built.

Scientists believe this happens because the genetic mutation alone isn’t enough to cause an attack. It usually requires a “second hit” from outside factors [6][7]. These modifiers can include:

  • Genetic Modifiers: Other genes, such as CYP2D6, may influence how your body handles medications or toxins, making you more or less likely to have symptoms [8][9].
  • Environmental Factors: Your lifestyle, diet, and even your hormones play a massive role in whether the disease remains “silent” [10][11].
  • Biological Modifiers: Factors like age, sex, and the health of your mitochondria (the energy-producing parts of your cells) can also impact penetrance [10].

Three Stabilizing Facts for Your Journey

  1. You can lead a normal life. Most carriers remain asymptomatic (without symptoms) for their entire lives [3][4]. By learning to manage your environment, you can significantly reduce the risk of ever experiencing an attack [3][12].
  2. Knowing your triggers is your best defense. Attacks are typically caused by specific triggers that increase the liver’s demand for heme. These include certain medications, fasting or low-calorie diets, alcohol, and hormonal changes (such as the menstrual cycle) [12][13][7]. Avoiding these triggers is the most effective way to stay healthy [3].
  3. Highly effective treatments exist. If you do experience an attack, modern medicine has powerful tools to help. Treatments like hemin therapy work by “turning off” the overproduction of toxic precursors [6][14]. For those with frequent attacks, newer therapies like givosiran have revolutionized care by significantly reducing the number of attacks and improving quality of life [15][16].

Next Steps for Prevention

  • Check Your Medications: Many common drugs can trigger an attack. Always consult a porphyria-specific drug database (like drugs-porphyria.org) before starting something new [6].
  • Maintain Stable Energy: Avoid fasting or extreme dieting. Eating a healthy, well-balanced diet and not skipping meals can help keep your liver stable and prevent the buildup of toxic precursors [6].
  • Identify Your Care Team: It is helpful to find a doctor or specialist who is familiar with rare metabolic diseases to guide your long-term monitoring, which may include annual checkups for your liver and kidney health [6][17].

Common questions in this guide

What triggers an acute porphyria attack?
Attacks are usually triggered by factors that increase the liver's demand for heme. Common triggers include fasting, low-calorie diets, alcohol, hormonal changes during the menstrual cycle, and starting certain new medications.
Will everyone with the HMBS mutation develop porphyria symptoms?
No, only about 1% to 2% of people with the gene mutation ever develop symptoms. This is known as low penetrance, meaning the genetic change alone is rarely enough to cause an attack without other environmental or biological triggers.
How is an acute intermittent porphyria attack treated?
Severe attacks are typically treated with hemin therapy, which helps stop the overproduction of toxic substances in the liver. For patients with frequent attacks, newer medications like givosiran can help prevent them.
What kind of doctor should I see for HMBS-related porphyria?
It is best to consult a specialist familiar with rare metabolic diseases, such as a geneticist, hepatologist, or a dedicated porphyria specialist. They can help manage your long-term monitoring and coordinate emergency care.
How can I find out if my medications are safe for porphyria?
You should always check any new medications or supplements against a specialized porphyria drug database. Your doctor or pharmacist can help review these databases to ensure a drug will not trigger an attack.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific mutation was found in my HMBS gene, and what does it tell you about my risk?
  2. 2.Can you help me review my current medications and supplements against a porphyria safety database?
  3. 3.If I experience a severe attack of abdominal pain, what is the specific protocol for emergency treatment at this hospital?
  4. 4.How often should I have my urine porphobilinogen (PBG) levels checked, and what do those levels mean for my risk of an attack?
  5. 5.Do you have experience treating other AIP patients, or should I be referred to a porphyria specialist?
  6. 6.What is the process for testing my first-degree relatives (parents, siblings, children) for this mutation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Diagnosis and Treatment of Acute Intermittent Porphyria.

    Bai J, Wang ZH

    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 2017; (39(6)):836-840 doi:10.3881/j.issn.1000-503X.2017.06.017.

    PMID: 29338831
  2. 2

    Therapeutic approach to acute crises of hepatic porphyrias.

    Garrido Montes M, Pertusa Mataix R, Garcia Morillo JS

    Revista clinica espanola 2024; (224(10)):664-669 doi:10.1016/j.rceng.2024.09.004.

    PMID: 39313028
  3. 3

    Self-efficacy and self-management strategies in acute intermittent porphyria.

    Hammersland MH, Aarsand AK, Sandberg S, Andersen J

    BMC health services research 2019; (19(1)):444 doi:10.1186/s12913-019-4285-9.

    PMID: 31269991
  4. 4

    Functional and structural analysis of a novel splice site HMBS variant in a Chinese AIP patient.

    Wang X, Zhang H, Huang H, et al.

    Frontiers in genetics 2023; (14()):1333111 doi:10.3389/fgene.2023.1333111.

    PMID: 38192441
  5. 5

    The diagnosis of acute intermittent porphyria combined with seizures: Case report.

    Wang Z, Cheng L, Liang X, et al.

    Medicine 2023; (102(50)):e36167 doi:10.1097/MD.0000000000036167.

    PMID: 38115298
  6. 6

    Acute Hepatic Porphyrias: Review and Recent Progress.

    Wang B, Rudnick S, Cengia B, Bonkovsky HL

    Hepatology communications 2019; (3(2)):193-206 doi:10.1002/hep4.1297.

    PMID: 30766957
  7. 7

    Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.

    Bustad HJ, Kallio JP, Vorland M, et al.

    International journal of molecular sciences 2021; (22(2)) doi:10.3390/ijms22020675.

    PMID: 33445488
  8. 8

    High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor.

    Barreda-Sánchez M, Buendía-Martínez J, Glover-López G, et al.

    Orphanet journal of rare diseases 2019; (14(1)):59 doi:10.1186/s13023-019-1031-7.

    PMID: 30808393
  9. 9

    Molecular genetic study of acute intermittent porphyria in Russia: HMBS gene mutation spectrum and problem of penetrance.

    Goncharova M, Pshenichnikova O, Luchinina Y, et al.

    Clinical genetics 2019; (96(1)):91-97 doi:10.1111/cge.13558.

    PMID: 31044425
  10. 10

    Acute intermittent porphyria: a disease with low penetrance and high heterogeneity.

    Lei JJ, Li S, Dong BX, et al.

    Frontiers in genetics 2024; (15()):1374965 doi:10.3389/fgene.2024.1374965.

    PMID: 39188285
  11. 11

    [Abdominal pain and severely impaired consciousness in a 19-year-old female patient].

    Kozlov A, Mybes C, Falk N, et al.

    Innere Medizin (Heidelberg, Germany) 2025; (66(11)):1203-1208 doi:10.1007/s00108-025-01939-9.

    PMID: 40668375
  12. 12

    Identification and characterization of 40 novel hydroxymethylbilane synthase mutations that cause acute intermittent porphyria.

    Chen B, Solis-Villa C, Erwin AL, et al.

    Journal of inherited metabolic disease 2019; (42(1)):186-194 doi:10.1002/jimd.12040.

    PMID: 30740734
  13. 13

    Molecular Analysis of 55 Spanish Patients with Acute Intermittent Porphyria.

    Morán-Jiménez MJ, Borrero-Corte MJ, Jara-Rubio F, et al.

    Genes 2020; (11(8)) doi:10.3390/genes11080924.

    PMID: 32806544
  14. 14

    Effect of Menstrual Cycle on Acute Intermittent Porphyria.

    Júnior VRS, Lemos VMV, Feitosa IML, et al.

    Child neurology open 2017; (4()):2329048X17736170 doi:10.1177/2329048X17736170.

    PMID: 29094055
  15. 15

    German Real-World Experience of Patients with Diverse Features of Acute Intermittent Porphyria Treated with Givosiran.

    Kubisch I, Wohmann N, Wissniowski TT, et al.

    Journal of clinical medicine 2024; (13(22)) doi:10.3390/jcm13226779.

    PMID: 39597922
  16. 16

    Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study.

    Sardh E, Balwani M, Rees DC, et al.

    Orphanet journal of rare diseases 2024; (19(1)):365 doi:10.1186/s13023-024-03284-w.

    PMID: 39363243
  17. 17

    Liver transplantation and primary liver cancer in porphyria.

    Lissing M, Wang B, Wahlin S

    Liver international : official journal of the International Association for the Study of the Liver 2025; (45(3)):e15894 doi:10.1111/liv.15894.

    PMID: 38456621

This page is for informational purposes only and does not replace professional medical advice. Always consult your porphyria specialist or healthcare provider before changing your diet, lifestyle, or medications.

Get notified when new evidence is published on HMBS-related hepatic porphyria.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.